<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03939403</url>
  </required_header>
  <id_info>
    <org_study_id>IB-0319-002</org_study_id>
    <nct_id>NCT03939403</nct_id>
  </id_info>
  <brief_title>Conventional Ovarian Stimulation vs. Single Injection Stimulation of Corifollitropin Alfa in Oocyte Donor</brief_title>
  <acronym>TAIL</acronym>
  <official_title>Conventional Ovarian Stimulation vs. Single Injection Stimulation of Corifollitropin Alfa in Oocyte Donor. A Randomized Clinical Trial. TAIL Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Bernabeu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Bernabeu</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to study the efficiency of using a single injection of Corifollitropin alfa
      for ovarian stimulation by initiating administration late and without further administration
      of follicle-stimulating hormone after the 7th day of stimulation compared to conventional
      ovarian stimulation using Corifollitropin alfa (drug administration 5 days after cessation of
      hormonal contraceptive and supplementation with follicle-stimulating hormone daily
      administration from the 8th day of stimulation).

      This a controlled randomized clinical study and 180 patients will be recruited (90 per arm)
      and the primary study outcome is the number of obtained oocytes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of oocytes</measure>
    <time_frame>At the end of stimulation</time_frame>
    <description>Number of oocytes after stimulation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Ovarian Stimulation</condition>
  <arm_group>
    <arm_group_label>7-days pill free interval</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5-days pill free interval</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Time of administration of Corifollitropin Alfa</intervention_name>
    <description>The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.
The control grup will receive the treatment on the 5th day after the cessation of hormonal contraceptive use. The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.
The intervention grup will receive the treatment on the 7th day after the cessation of hormonal contraceptive use.</description>
    <arm_group_label>7-days pill free interval</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible for oocyte donation program

          -  Age between 18 and 32 years old

          -  BMI &gt;18 and &lt;30

          -  Antral follicle count &gt;12 (summing both ovaries)

          -  Presence of both ovaries

          -  Ability to participate in and comply with study protocol

          -  Signed informed consent

          -  No treatment with ovulation stimulators in the 3 months prior to the start of
             stimulation.

        Exclusion Criteria:

          -  Diagnosis of endometriosis at any stage

          -  AFC &gt;20

          -  Polycystic ovary syndrome

          -  Concurrent participation in another study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>32 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna Pitas</last_name>
    <phone>+34663926079</phone>
    <email>apitas@institutobernabeu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto Bernabeu</name>
      <address>
        <city>Alicante</city>
        <zip>03016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 3, 2019</study_first_submitted>
  <study_first_submitted_qc>May 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Bernabeu</investigator_affiliation>
    <investigator_full_name>Joaquín Llácer</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

